ADZYNMA 500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Introduction

Package Leaflet: Information for the User

ADZYNMA 500UI powder and solvent for solution for injection

ADZYNMA 1500UI powder and solvent for solution for injection

rADAMTS13

This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. 1. What ADZYNMA is and what it is used for
2. What you need to know before you use ADZYNMA
3. How to use ADZYNMA
4. Possible side effects
5. Storage of ADZYNMA
6. Contents of the pack and other information
7. Instructions for use

1. What ADZYNMA is and what it is used for

ADZYNMA contains the active substance rADAMTS13, a synthetic copy of the natural enzyme (protein) ADAMTS13. People with congenital thrombotic thrombocytopenic purpura (TTP) lack this enzyme.

Congenital TTP is a very rare inherited blood disorder that causes blood clots to form in small blood vessels. These clots can block the flow of blood and oxygen to organs, resulting in a lower than normal number of platelets (components of blood that help it clot) in the blood.

Congenital TTP is caused by a lack of the enzyme ADAMTS13 in the blood. ADAMTS13 helps prevent blood clots from forming by breaking down large molecules called von Willebrand factor (VWF). When VWF molecules are too large, they can cause dangerous blood clots. ADZYNMA is used to replace ADAMTS13 levels, which helps break down these large molecules into smaller ones. This reduces the likelihood of blood clots forming and can prevent low platelet levels in people with TTP.

2. What you need to know before you use ADZYNMA

Do not use ADZYNMA

• If you have had severe or life-threatening allergic reactions to rADAMTS13 or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting treatment with ADZYNMA.

Allergic reactions

There is a risk of experiencing an allergic reaction with ADZYNMA. Your doctor should inform you about the immediate signs of severe allergic reactions, such as:

• rapid heartbeat
• chest tightness
• wheezing and/or sudden difficulty breathing
• low blood pressure
• hives, rash, and itching of the skin
• runny or stuffy nose
• red eyes
• sneezing
• rapid swelling under the skin in areas such as the face, throat, arms, and legs
• fatigue
• nausea (feeling sick)
• vomiting
• feeling of numbness, tingling, or muscle pain
• restlessness
• anaphylaxis (a severe allergic reaction that can cause difficulty swallowing and/or breathing and redness or swelling of the face and/or hands).

If you experience any of these symptoms, your doctor will decide whether treatment with ADZYNMA should be stopped and will provide you with the necessary medication to treat the allergic reaction. Severe symptoms, including difficulty breathing and dizziness, require urgent treatment.

Inhibitors

Neutralizing antibodies (called inhibitors) may develop in some patients receiving ADZYNMA. These inhibitors could potentially cause the treatment to stop working properly. Inform your doctor if you think the medicine is not working for you.

Other medicines and ADZYNMA

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

You should not receive ADZYNMA during pregnancy unless your doctor specifically recommends it. You and your doctor will need to decide whether you can use ADZYNMA during breastfeeding.

Driving and using machines

The influence of this medicine on the ability to drive and use machines may be small. After using ADZYNMA, dizziness and drowsiness may occur.

Keeping a record

In order to improve the traceability of biological medicinal products, the name and batch number of the product should be clearly recorded.

ADZYNMA contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per vial; this is essentially "sodium-free".

ADZYNMA contains polysorbate 80

This medicine contains 2.7 mg of polysorbate 80 in each vial of ADZYNMA 500 UI or 1,500 UI, equivalent to up to 0.216 mg/kg. Polysorbates can cause allergic reactions. Inform your doctor if you have any known allergies.

3. How to use ADZYNMA

Treatment with ADZYNMA will be given under the supervision of a doctor experienced in the treatment of patients with blood disorders.

ADZYNMA is given by injection into a vein. It is provided to your doctor as a powder that is dissolved (reconstituted) with the solvent (a liquid in which the powder can be dissolved) supplied before administration.

The dose is calculated based on your body weight.

Administration of the medicine at home

Your doctor may consider using ADZYNMA at home if you tolerate the injections well. When you are able to inject ADZYNMA (or have it administered by a caregiver) after receiving the relevant training from your doctor or nurse, your doctor will continue to monitor your response to treatment. If you notice any side effects while using the medicine at home, stop the injection immediately and seek medical attention.

Recommended dose

Preventive enzyme replacement therapy

The usual dose is 40 UI per kilogram of body weight, given every two weeks.

Your doctor may change the frequency to once a week if administration of ADZYNMA every two weeks does not work for you.

On-demand enzyme replacement therapy for acute TTP episodes

If you develop an acute episode of thrombotic thrombocytopenic purpura (TTP), the recommended dose of ADZYNMA is as follows:

• 40 UI/kg of body weight on day 1.
• 20 UI/kg of body weight on day 2.
• 15 UI/kg of body weight once daily, starting on day 3 and until two days after the acute TTP episode has resolved.

If you use more ADZYNMA than you should

Using too much of this medicine can cause bleeding.

If you forget to use ADZYNMA

If you have missed an injection of ADZYNMA, inform your doctor as soon as possible. Do not take a double dose to make up for forgotten doses.

If you stop treatment with ADZYNMA

If you want to stop treatment with ADZYNMA, consult your doctor. If you stop treatment, the symptoms of the disease may worsen.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been reported with ADZYNMA:

Very common(may affect more than 1 in 10 people)

• nasal and throat infection
• headache
• feeling of dizziness
• migraine
• diarrhea
• nausea

Common(may affect up to 1 in 10 people)

• high platelet count in the blood (thrombocytosis)
• drowsiness
• constipation
• bloating (abdominal distension)
• weakness (asthenia)
• feeling of warmth
• abnormal ADAMTS13 activity

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of ADZYNMA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month stated.

Unopened vials

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Store in the original package to protect from light.

Unopened ADZYNMA powder vials can be stored at room temperature (up to 30°C) for a period of up to 6 months, but not beyond the expiry date. Do not put ADZYNMA back in the refrigerator after it has been stored at room temperature. Record the date you removed ADZYNMA from the refrigerator on the carton.

After reconstitution

Discard the reconstituted medicine that is not used within 3 hours.

Do not use this medicine if you notice it is not clear and colorless.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

Composition of ADZYNMA

• The active substance, ADAMTS13, is a recombinant human "disintegrin A and metalloproteinase with thrombospondin motifs 13" purified.

The nominal content of each vial of powder is 500 or 1,500 IU of rADAMTS13 activity.

• The vial of solvent contains 5 ml of water for injectable preparations.
• The other excipients are sodium chloride, calcium chloride dihydrate, L-histidine, mannitol, sucrose, and polysorbate 80 (E433). See section 2 "ADZYNMA contains sodium" and "ADZYNMA contains polysorbate 80".

Appearance of the Product and Container Contents

ADZYNMA is supplied as a powder and solvent for solution for injection. The powder is a white lyophilized powder. The solvent is clear and colorless.

Each container contains a vial of powder, a vial of solvent, a reconstitution device (BAXJECT II Hi-Flow), a disposable syringe, an infusion set, and two alcohol swabs.

Marketing Authorization Holder and Manufacturer

Takeda Manufacturing Austria AG

Industriestrasse 67

1221 Vienna

Austria

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Date of Last Revision of this Leaflet: 08/2024.

This medicinal product has been authorized under "exceptional circumstances". This means that due to the rarity of this disease, it has not been possible to obtain complete information on this medicinal product.

The European Medicines Agency will review any new information that may become available every year and this leaflet will be updated as necessary.

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

1. Instructions for Use

These instructions contain information on how to reconstitute and infuse ADZYNMA.

These instructions for use are intended for healthcare professionals and patients/caregivers who administer ADZYNMA at home after receiving proper training from a healthcare professional.

Treatment with ADZYNMA should be prescribed and supervised by a healthcare professional with experience in the treatment of patients with blood disorders.

Important:

• For intravenous injection only after reconstitution.
• Use aseptic technique throughout the procedure.
• Check the expiration date of the product before use.
• Do notuse ADZYNMA if the expiration date has passed.
• If a patient needs more than one vial of ADZYNMA per injection, reconstitute each vial according to the detailed instructions indicated in "Reconstitution".
• Inspect the reconstituted ADZYNMA solution for particles or color changes before administration. The solution should be clear and colorless.
• Do notadminister if particles or color changes are observed.
• If stored at room temperature, use ADZYNMA before 3 hourshave passed since reconstitution.
• Do notadminister ADZYNMA in the same tube or container and simultaneously with other infusion medications.

Reconstitution

1. Prepare a clean and flat surface and gather all necessary materials for reconstitution and administration (Figure A).

1. Allow the ADZYNMA and solvent vials to reach room temperature before use.
2. Wash and dry your hands thoroughly.
3. Remove the plastic caps from the ADZYNMA and solvent vials and place the vials on a flat surface (Figure B).

Figure B

1. Clean the rubber stoppers with an alcohol swab and let them dry before use (Figure C).

Figure C

1. Open the BAXJECT II Hi-Flow device package by removing the cap, without touching the inside (Figure D).
   • Do notremove the BAXJECT II Hi-Flow device from the package.
   • Do nottouch the transparent plastic tip.

Figure D

1. Turn the package with the BAXJECT II Hi-Flow device upside down and place it over the top of the solvent vial. Press straight down until the transparent plastic tippunctures the vial stopper(Figure E).

Figure E

1. Hold the BAXJECT II Hi-Flow device package by the edge and remove it from the device (Figure F).
   • Do notremove the blue capfrom the BAXJECT II Hi-Flow device.
   • Do nottouch the exposed purple plastic tip.

Figure F

1. Turn the system upside downso that the vial of solventis on top. Press the BAXJECT II Hi-Flow device straight down until the purple plastic tippunctures the stopper of the ADZYNMA powder vial(Figure G). The vacuum will cause the solvent to flow into the ADZYNMA powder vial.
   • You may observe bubbles or foam; this is normal and should disappear soon.

Figure G

1. Gently and continuously turn the connected vials in a circular motion until the powder is completely dissolved (Figure H).
   • Do notshake the vial.

Figure H

1. Before administration, visually inspect the reconstituted solution for particles.
   • Do notuse the product if particles or color changes are observed.
2. If the dose requires more than one vial of ADZYNMA, reconstitute each vial following the above steps.
   • Use a different BAXJECT II Hi-Flow device to reconstitute each ADZYNMA vial.

Administration of ADZYNMA

1. Remove the blue capfrom the BAXJECT II Hi-Flow device (Figure I). Connect a Luer-Lock syringe (Figure J).
   • Do notinject air into the system.

1. Turn the system upside down(so that the vial with ADZYNMA is on top). Withdraw the reconstituted solutioninto the syringe by slowly pulling the plunger (Figure K).

Figure K

1. If a patient is to receive more than one vial of ADZYNMA, the contents of several vials can be withdrawn into the same syringe. Repeat this process with all reconstituted ADZYNMA vials until the total administration volume is reached.
2. Disconnect the syringe and connect an appropriate injection needle or infusion set.
3. Point the needle upwards and eliminate air bubbles by gently tapping the syringe with your finger and slowly and carefully expelling the air from the syringe and needle.
4. Apply a tourniquet and clean the chosen injection site with an alcohol swab (Figure L).

Figure L

1. Insert the needle into the vein and remove the tourniquet.
2. Infuse the reconstituted ADZYNMA slowly, at a rate of 2 to 4 ml per minute(Figure M).
   • A syringe pump can be used to control the administration rate.

Figure M

1. Remove the needle from the vein and apply pressure to the injection site for several minutes.
   • Do notrecap the needle.

Storage of ADZYNMA

• Store ADZYNMA in the refrigerator (between 2°C - 8°C) or at room temperature (up to 30°C) for a period of up to 6 months.
• Do notreturn ADZYNMA to the refrigerator after storage at room temperature.
• Recordthe date ADZYNMA was removed from the refrigerator on the carton.
• Do notfreeze.
• Store in the original packaging to protect from light.
• Do notuse after the expiration date stated on the label and carton after EXP.
• Use ADZYNMA before 3 hourshave passed since reconstitution. Discard the reconstituted medicinal product that has not been used within 3 hours of reconstitution.

Disposal of ADZYNMA

• The vials are for single use.
• Discard the used needle, syringe, and empty vials in a puncture-resistant container for sharp objects.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.